Abstract Purpose: Microsatellite instability (MSI) testing of colorectal cancer tumors is used as a screening tool to identify patients most likely to be mismatch repair (MMR) gene mutation carriers. We wanted to examine which microsatellite markers currently used to detect MSI best predict earlyonset colorectal cancer caused by germ-line mutations in MMR genes. Experimental Design: Invasive primary tumors from a population-based sample of 107 cases of colorectal cancer diagnosed before age 45 years and tested for germ-line mutations in MLH1, MSH2, MSH6, and PMS2 and MMR protein expression were screened for MSI using the National Cancer Institute panel and an expanded 10-microsatellite marker panel. MSI-High cancers and all MLH1 and MSH2 mutation carriers (100% sensitive). Bat40 and Bat25 were unstable in all tumors of MSH6 mutation carriers (100% sensitive). Bat40 was unstable in all MMR gene mutation carriers (100% sensitive). By incorporating seven mononucleotide repeats markers into the 10-marker panel, we were able to distinguish the carriers of MSH6 mutations (all scored 10 MSI-Low) from the MLH1 and MSH2 mutation carriers (all scored 10 MSI-High). Conclusions: In early-onset colorectal cancer, a microsatellite panel containing a high proportion of mononuclear repeats can distinguish between tumors caused by MLH1 and MSH2 mutations from those caused by MSH6 mutations.
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Only a small proportion of early-onset colorectal cancer is thought to be due to mutations in mismatch repair (MMR) genes, perhaps <20% (1) . Not all individuals with early-onset colorectal cancer (i.e., diagnosed under the age of 45 years) who carry mutations in these genes have a family history sufficient for classification as hereditary nonpolyposis colorectal cancer (1, 2) , and this observation is rarely due to de novo mutations (3, 4) . However, once identified, MMR gene mutation carriers and their families can benefit from improved clinical management that includes appropriate surveillance procedures, treatment options, and predictive testing for unaffected family members.
Given that genetic testing for germ-line mutations in MMR genes is technically challenging and costly, screening strategies have been developed to better identify the individuals with colorectal cancer who are most likely to carry a germ-line MMR gene mutation. These strategies include examining the expression of MMR proteins in tumor material using immunohistochemistry, testing for tumor microsatellite instability (MSI), and taking a family history of colorectal cancer and other cancers thought to be caused by MMR mutations (1, 5, 6) . However, practical and local issues, such as the availability of sufficient laboratory-based expertise, may limit the application of these strategies. Therefore, refining and understanding the potential of each strategy as a stand-alone screening method for identifying likely carriers of MMR gene mutations requires further attention. In this study, we have focused on MSI testing.
Although the definition of MSI and methodologies applied to detect it, including the nature and number of microsatellite markers used, have varied across studies (1, 7 -9) , it is thought that f15% of all colorectal cancer (10) and f30% of earlyonset colorectal cancer (1) display some degree of MSI. However, only a small proportion (10-20%) of all colorectal cancer that display MSI have identifiable underlying mutations in MMR genes. A substantial proportion of MSI-positive tumors are due to MLH1 promoter methylation, particularly the lateonset cases (11, 12) .
In a recent study of early-onset colorectal cancer, we reported that having a MSI-High tumor had a positive predictive value of 0.7 (95% confidence interval, 0.5-0.9) for having an identifiable germ-line mutation in any of four MMR genes: MLH1, MSH2, MSH6, or PMS2 (1). In a study of MSI in a hospital series of colorectal cancer, examination of just mononucleotide repeat markers was sufficient for the identification of tumors with MMR defects, as defined by lack of immunohistochemical staining for MLH1, MSH2, MSH6, and PMS2 (8) . However, that study did not report germ-line MMR gene status of these cancers. As the identification of individuals with germ-line MMR mutations is the important clinical end point (rather than simply the identification of MMR deficiency), the findings of this report may be difficult to interpret.
Unfortunately, there has been great variability in markers that have been used in reports of MSI in colorectal cancer and, as there is evidence that the sensitivity and specificity of markers to detect MSI differ across markers, it is not easy to compare and combine published data. The precise composition of an ideal panel for the identification of MSI in MMR gene mutation carriers continues to evolve. Some reports have suggested that the poly-A repeat in Bat26 is alone sufficient for MSI testing (13, 14) but others have shown variability (see refs. 8, 15 for examples). There is also evidence from the MSI testing of extracolonic hereditary nonpolyposis colorectal cancer -related tumors that microsatellites display tissue-specific vulnerability to instability in the presence of MMR gene mutations (16, 17) . A five-microsatellite marker panel for the detection of MSI was recommended in a report of a meeting on MSI at the National Cancer Institute (NCI) in 1998 (7). This panel, the ''NCI panel,'' has been used extensively in clinical and research settings.
Here, we report the details of MSI testing done using a 10-microsatellite marker panel in a population-based, case-family study of early-onset colorectal cancer conducted in Victoria (Australia). We compare our 10-marker panel with the NCI panel for specificity and sensitivity of MMR protein expression and germ-line MMR gene mutation status.
Materials and Methods
Subjects. The Victorian Colorectal Cancer Family Study is a population-based, case-control family study of early-onset colorectal cancer, conducted from 1993 to 1997 on 131 cases of histologically verified primary adenocarcinomas of the colon or rectum registered on the Victorian Cancer Registry (1, 18) . The probands (all diagnosed between 18 and 44 years of age) consisted of 66 females and 65 males, with the mean age at diagnosis being 39.5 years (SD, 4.7 years). Probands and their living relatives were asked to provide a blood sample and sign an informed consent, to allow access to their tumor tissues from pathology laboratories for use in molecular analyses. The study was approved by the ethics committees of The University of Melbourne and The Cancer Council Victoria.
Tumor specimens. Samples of invasive tumors from primary colorectal adenocarcinoma, and from other cancer diagnoses when available, were obtained from hospitals and private pathology laboratories for 118 (90%) case patients. Six probands did not consent to release tissue to the study and two laboratories had not agreed to release the remaining seven samples at the time of this study. All tumor samples were reviewed by a pathologist who directed the microdissection.
Testing for tumor MSI. MSI testing was done on invasive tumor cells microdissected from 5-Am sections of paraffin-embedded archival tumor tissue stained with 1% methyl green. DNA extracted from histologically normal cells microdissected from colonic or lymph node tissue, or DNA extracted from peripheral blood lymphocytes, was used to control the assay as described previously (1, 16, 19) . Ten microsatellite markers were assessed: 3 dinucleotide repeats (D5S346, D17S250, and D2S123) and 7 mononucleotide repeats (BAT25, BAT26, BAT40, MYB, TGFhRII, IGFIIR, and BAX). For the purpose of this study, the degree of instability in each tumor was scored in two ways. The first used data from all 10 markers to categorize tumors as microsatellite stable ( 10 MS-Stable), low ( 10 MSI-Low), and high ( 10 MSI-High) when 0 to 1, 2 to 5, and 6 to 10 markers, respectively, were identified as unstable (1, 16 (7) . Assessment of MSI was not successful for 11 (10%) tumor samples due to technical reasons related to tumor DNA quality, leaving 107 tested tumors, which included 106 colorectal, and one stomach tumor (collected from a case where the colorectal cancer could not be located at the diagnostic laboratory).
Testing for germ-line MMR gene mutations. As reported previously in detail (1), all exonic and flanking intronic sequences of the MLH1, MSH2, MSH6, and PMS2 were screened for germ-line mutations using sequencing approaches, except for exon 4 of MSH6 that was screened in eight overlapping fragments using denaturing high-pressure liquid chromatography. The multiplex ligation-dependent probe amplification assay (MCR-Holland; ref. 20) to detect large genomic alterations in MLH1 and MSH2 was performed on samples from probands that had tumors lacking at least one MMR protein expression and for which no previous mutation had been identified by sequencing. Break points were characterized by long-range PCR encompassing the predicted genomic alteration, cloning, and sequencing (3). Mutation testing was conducted for all case patients with the one or more of the following characteristics: (a) having a family history that fulfilled the Amsterdam Criteria for hereditary nonpolyposis colorectal cancer, (b) having a tumor that was MSI-High, or MSI-Low, or that lacked expression of at least one MMR protein; and (c) being in a random sample of 23 selected from those who had tumors that were MS-Stable and did not lack expression of any MMR protein. Of the 18 mutations detected, 15 (83%) were predicted to produce a truncated protein product (4 were alterations in splice site regions, 7 were frameshift mutations, 2 were nonsense mutations, and 2 were large deletions). The remaining three were a missense mutation, and two small in-frame deletions all considered deleterious (1).
Testing for tumor expression of MMR genes. The expression of MLH1, MSH2, MSH6, and PMS2 was assessed by immunohistochemistry testing on 3-Am formalin-fixed paraffin-embedded sections using standard methods, monoclonal antibodies MLH1 (PharMingen clone G168-728), MSH2 (Oncogene clone FE11), MSH6 (BD Transduction Laboratories clone 44), and PMS2 (PharMingen clone A16-4) on a DAKO autostainer. Normal colonic epithelium adjacent to tumor and lymphocytes served as inbuilt positive controls. A gastrointestinal pathologist scored the tumors as positive when nuclear staining in tumor tissue was present, or otherwise as negative. Table 1 shows the results of the MSI testing using both the 10-marker and the NCI (5 markers) panel scoring systems. Of the 17 tumors scored as 10 MSI-Low, only 3 were scored as NCI MSI-Low (cases 74-76) and the others were NCI MSS (n = 1, Fig. 1 ; Table 1 ). Table 1 shows that 24 of the 26 (92%) cancers that lacked the expression of at least one of the MMR genes were positive for MSI. All four tumors arising in individuals with germ-line mutations in MSH6 lacked the protein expression of MSH6 and were scored as 10 MSI-Low and NCI MSI-High. None of these MSH6 mutation carriers had more than one unstable dinucleotide repeat.
Results
Forty-nine (46%) of the primary early-onset cancers screened for MSI had one or more unstable markers. Table 2 shows that the most frequently unstable marker was Bat40, found to be unstable in 28 (26%) tumor DNA samples. The microsatellite marker found to be least frequently unstable was IGFIIR (6 of 107, 6%). Bat26, Bat40, and Myb were found to be unstable in all the 10 MSI-High cancers and thus in all the MLH1 and MSH2 mutation carriers (100% sensitive). Bat40 was also unstable in the tumors in cases known to carry MSH6 mutations and thus was unstable in all 17 known MMR gene mutation carriers (100% sensitive).
Discussion
How specific and sensitive can MSI testing of colorectal cancer diagnosed at an early age (before 45 years) be for the identification of MMR gene mutations carriers? We have examined this question using a population-based case-family study of colorectal cancer diagnosed before the age of 45 years and found that MSI had a predictive value of 0.7 (95% confidence interval, 0.5-0.9) for having an identifiable germline mutation in any of four MMR genes (1) .
Dissecting the MSI test into microsatellite marker components revealed some interesting aspects. Expansion of the microsatellite panel to include additional mononucleotide repeats was advantageous. Similarly to Hatch et al. (8) , who reported that examination of mononucleotide repeats was sufficient for the identification of tumors with MMR defects, we found that the four microsatellite markers most sensitive to the detection of MSI in MMR gene mutation carriers were the mononucleotide repeats Bat40, Bat26, Bat25, and Myb; they detected MSI in 100%, 94%, 94%, and 88% of the carriers, respectively. The persistence of these mononucleotide markers to detect MSI in the group defined as 10 MSI-Low (and the poor sensitivity of dinucleotide repeats to detect MSI in this group) enable the identification of a 10 MSI-Low group that was predominantly mononucleotide unstable and contained all the MSH6 mutation carriers (cases 73-89; Table 1 ). As presented and discussed previously (1, 3, 21) , the group of tumors defined as 10 MSI-Low have a significant level of MSI [12] 7 [8] 13 [15] 9 [10] 11 [12] 11 [12] 15 [17] 1 [1] 6 [7] *Excluding the PMS2 mutation carrier. 
